PARI

Former Chief Scientist of the United States Air Force Dr. Mark J. Lewis Appointed to Voyager Space Advisory Board

Retrieved on: 
Tuesday, September 26, 2023
Pentagon, Defense Department Advisory Committee on Women in the Services, University, Voyager (Space Needle album), Defense, Under Secretary of Defense for Research and Engineering, National Defense Research University, Research, National Defense Industrial Association, Voyager, Government, History of the University of Maryland, College Park, Department of Defence, PARI, Purdue University, United States Department of the Air Force, Food security, Management, Engineering

DENVER, Sept. 26, 2023 /PRNewswire/ -- Voyager Space (Voyager), a global leader in space exploration, today announced Dr. Mark J. Lewis has joined the company's advisory board.

Key Points: 
  • DENVER, Sept. 26, 2023 /PRNewswire/ -- Voyager Space (Voyager), a global leader in space exploration, today announced Dr. Mark J. Lewis has joined the company's advisory board.
  • A renowned researcher, professor and former deputy undersecretary of defense, Dr. Lewis brings extensive expertise across national security, scientific discovery and academic research to Voyager.
  • He joins a renowned group of best-in-class experts guiding Voyager as it continues its mission of building a better future for humanity in space and on Earth.
  • Voyager is at the forefront of commercial space innovation, and I know this is only the beginning," said Dr. Lewis.

Purdue Applied Research Institute opens $41M Hypersonics and Applied Research Facility

Retrieved on: 
Wednesday, June 7, 2023
Schweitzer Engineering Laboratories, Workforce, Mach, Maurice, Travel, Student, WEST, Rolls-Royce, Boilermaker, University, Research, Moon, Wind, Saab, PARI, Atmosphere, Sound, Knowledge, Federation, Hypersonic speed, Department of Defence, Aircraft, Renewable energy, Nursing, Purdue University, Stratolaunch Systems

WEST LAFAYETTE, Ind., June 6, 2023 /PRNewswire-PRWeb/ -- The Purdue Applied Research Institute (PARI), the applied research arm of Purdue University, on Tuesday (June 6) officially opened a new facility dedicated to enhancing Purdue's world-leading capabilities in hypersonics evaluation and testing.

Key Points: 
  • Purdue's $41 million, 65,000-square-foot Hypersonics and Applied Research Facility is an investment in test and evaluation and research capabilities.
  • WEST LAFAYETTE, Ind., June 6, 2023 /PRNewswire-PRWeb/ -- The Purdue Applied Research Institute (PARI), the applied research arm of Purdue University, on Tuesday (June 6) officially opened a new facility dedicated to enhancing Purdue's world-leading capabilities in hypersonics evaluation and testing.
  • "The Hypersonic Applied Research Facility is an investment in test and evaluation and research capabilities that this country desperately needs," said Mark Lewis, chief executive officer for PARI.
  • The Mach 8 quiet wind tunnel and the HYPULSE tunnel offer controlled environments to research several facets of high-speed flight.

Avalyn Pharma Reports Data After One Year of Treatment in Ongoing AP01 Open-label Extension Trial in Adults with Pulmonary Fibrosis

Retrieved on: 
Tuesday, April 11, 2023
Week, ATS, Pathology, PPF, ILD, FVC, American Thoracic Society, Cough, Pulmonary fibrosis, Literature, Spirometry, Vital capacity, Patient, BID, PARI, IPF, OLE, Idiopathic pulmonary fibrosis, Fatigue, ATLAS, Pharmaceutical industry, Thorax

The study (AP01-005) enrolled a total of 41 individuals with idiopathic pulmonary fibrosis (IPF) who had completed the AP01-002 Phase 1b ATLAS study.

Key Points: 
  • The study (AP01-005) enrolled a total of 41 individuals with idiopathic pulmonary fibrosis (IPF) who had completed the AP01-002 Phase 1b ATLAS study.
  • In addition, Avalyn enrolled two new cohorts of patients who had diagnoses of either IPF or progressive pulmonary fibrosis (PPF), a poorly served segment of the ILD market with high mortality rates.
  • Generally, AP01 was well tolerated with the most common treatment-related adverse events being cough, fatigue and oropharyngeal pain.
  • Avalyn plans to present additional details from this and other studies during medical congresses in 2023.

Avalyn Pharma Reports Results of Phase 1 Study of AP02 in Healthy Volunteers and Participants with Idiopathic Pulmonary Fibrosis

Retrieved on: 
Thursday, March 30, 2023
Aes, Pharmacokinetics, Cough, Șaeș, Dizziness, Patient, PARI, Nausea, Diagnosis, IPF, Headache, Idiopathic pulmonary fibrosis, Safety, Pharmaceutical industry

Seattle, March 30, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. , a clinical-stage biopharmaceutical company focused on development of targeted therapies for life-threatening pulmonary diseases, today reported top-line results from the company’s Phase 1 trial for AP02 (inhaled nintedanib) .

Key Points: 
  • Seattle, March 30, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. , a clinical-stage biopharmaceutical company focused on development of targeted therapies for life-threatening pulmonary diseases, today reported top-line results from the company’s Phase 1 trial for AP02 (inhaled nintedanib) .
  • AP02 was generally well tolerated, with no serious adverse events (SAEs) reported among the participants who were administered AP02.
  • “We were especially excited to see the tolerability results of AP02 in those participants with idiopathic pulmonary fibrosis (IPF), an underserved interstitial lung disease with survival rates between 3 and 5 years from diagnosis,” explained Lyn Baranowski , Avalyn’s CEO.
  • The most common adverse events (AEs) observed in the study and deemed related to AP02 were cough and headache followed by nausea and dizziness.

ReCode Therapeutics Announces First Participants Dosed in a Phase 1 Healthy Volunteer Clinical Trial of Novel Disease-Modifying Genetic Medicine, RCT1100 for the Treatment of Primary Ciliary Dyskinesia

Retrieved on: 
Wednesday, March 15, 2023
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, Clinical Trials, Conference, DSM-IV codes, Disease, Messenger, Quality of life, Therapy, SORT, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, LNP, Trial of the century, Cell, PARI, CFTR, International Conference on Emerging Infectious Diseases, Human, MBA, Toxicology, ATS, Respiratory failure, PCD, Safety, Clinical trial, Primary ciliary dyskinesia, American Thoracic Society, Cystic fibrosis, Investigational New Drug, Food, IND, Bronchiectasis, Recode, Pharmacology, Vaccine, DNAI1

Patients with PCD have a high burden of morbidity with chronic respiratory infections and bronchiectasis, and often develop respiratory failure.

Key Points: 
  • Patients with PCD have a high burden of morbidity with chronic respiratory infections and bronchiectasis, and often develop respiratory failure.
  • RCT1100 is designed to be a disease-modifying mRNA-based therapeutic for PCD caused by pathogenic mutations in DNAI1, a gene that encodes a protein essential for ciliary movement.
  • The intent is for the mRNA delivery to lead to DNAI1 protein production in target cells and thereby rescue ciliary function.
  • The study is being conducted in New Zealand and ReCode anticipates enrolling approximately 32 healthy adults who will receive a single dose of either placebo or RCT1100.

Medical device manufacturer PARI relies on automated S/4HANA transformation of its validated SAP environments powered by smartShift

Retrieved on: 
Thursday, January 19, 2023
GxP, SAP S/4HANA, Automation, PARI, Information technology, Documentation, SAP, Risk management

BOSTON, Jan. 19, 2023 /PRNewswire/ -- German medical device manufacturer PARI and smartShift, leading global provider of Intelligent Automation for SAP transformations based in Mannheim/Germany, announce their collaboration on the planned S/4HANA transformation for PARI group's validated SAP systems.

Key Points: 
  • BOSTON, Jan. 19, 2023 /PRNewswire/ -- German medical device manufacturer PARI and smartShift, leading global provider of Intelligent Automation for SAP transformations based in Mannheim/Germany, announce their collaboration on the planned S/4HANA transformation for PARI group's validated SAP systems.
  • PARI is currently transforming its core SAP systems to SAP S/4HANA.
  • "smartShift brings a lot of experience with the specifics of validated system environments in an industry like ours" says Edgar Osswald, Head of Information Technology & Digitization at PARI Group.
  • We look forward to bringing these benefits to PARI and ensuring a smooth S/4HANA transformation."

Global Chronic Obstructive Pulmonary Disease Treatment Devices Report to 2027 - Market Insights, Competitive Landscape and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Friday, September 30, 2022
Health, Cardiology, Adult, Invacare, Competitive landscape, Patient, Particle size, Degenerative disease, Disease, Death, Microlife Corporation, COVID-19, Prevalence, Food, LAICA, Growth, Novartis, Inhaler, COVID, Genetics, Lupinus, PARI, Health care, Asthma, Mortality, LABA, CAGR, Hospital, Risk, Phlegm, FDA, Population, Air pollution, GlaxoSmithKline, Nebulizer, Disorder, AstraZeneca, Tobacco, MHRA, WHO, COPD, Medication, Cough, Incidence, Chronic obstructive pulmonary disease, World Health Organization, Dust, Medtronic, Metered-dose inhaler, Regulation of tobacco by the U.S. Food and Drug Administration, LAMA, Smoking, Awareness, Noble gas, Pharmaceutical industry, Dentistry, Geography

The "Chronic Obstructive Pulmonary Disease Treatment Devices - Market Insights, Competitive Landscape and Market Forecast-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Chronic Obstructive Pulmonary Disease Treatment Devices - Market Insights, Competitive Landscape and Market Forecast-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global chronic obstructive pulmonary disease (COPD) treatment devices market is estimated to grow at a CAGR of 6.37% during the forecast period from 2022 to 2027.
  • Chronic Obstructive Pulmonary Disease Treatment Devices Market Dynamics:
    The chronic obstructive pulmonary disease treatment devices market is witnessing a growth in product demand owing to various reasons such as the growing prevalence of COPD due to long-term exposure to air pollution, secondhand smoke and dust, fumes and chemicals.
  • Furthermore, rise in consumption of tobacco among youth population is anticipated to bolster the market for chronic obstructive pulmonary disease treatment devices during the forecast period.

BRI Collaborates with PT Syngenta Indonesia through CENTRIGO™ Farming Ecosystem to Provide Financial Services for Farmers in Indonesia

Retrieved on: 
Tuesday, September 13, 2022
BBRI, Agriculture, BRI, Memorandum of understanding, Farmer, Growth, Bank, LOI, TBK, PT, PARI, Letter of intent, IDX, Ecosystem, SME, Multimedia, View, Seaweed, Renewable energy

(IDX: BBRI) collaborates with PT Syngenta Indonesiato provide financial services for farmers through theCENTRIGO Farming Ecosystem.

Key Points: 
  • (IDX: BBRI) collaborates with PT Syngenta Indonesiato provide financial services for farmers through theCENTRIGO Farming Ecosystem.
  • The end-to-end ecosystem, aimed to support farmers' needs and increase productivity and profitability, willbe launched in October 2022.
  • Thecollaboration involves various banking services provided by BRI for PT Syngenta Indonesia and all the stakeholders in its business ecosystem.
  • On the same occasion, Supari, Director of Micro Business of BRI, and Ronnie Keh, Director of PT Syngenta Indonesia, also signed a cooperation agreement on microcredits and digital solutions for farmers of the CENTRIGO Farming Ecosystem.

Insmed Names Drayton Wise Chief Commercial Officer

Retrieved on: 
Monday, May 23, 2022
Senior, Physician, Risk, ASPEN, Company, Population, General manager, Private Securities Litigation Reform Act, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Risk management, U.S. Securities and Exchange Commission, Environment, Disclosure, Patient, Amikacin, Government, Executive Committee, Nature, Liposome, COVID-19, Failure, Marketing, Novartis, PARI, Industry, Commercial, Time, Lists of disasters, Forward-looking statement, Safety, Attention, AstraZeneca, Drug development, INSM, SEC, Security (finance), Annual report, Pharmaceutical industry, Management, Insming

BRIDGEWATER, N.J., May 23, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the appointment of Drayton Wise as Chief Commercial Officer, effective May 23, 2022.

Key Points: 
  • BRIDGEWATER, N.J., May 23, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the appointment of Drayton Wise as Chief Commercial Officer, effective May 23, 2022.
  • "We are thrilled to promote Drayton to Chief Commercial Officer at this critical inflection point for Insmed, as we commercialize ARIKAYCE in three major territories and prepare for the potential global launch of brensocatib and potential label expansion of ARIKAYCE to a frontline patient population," said Will Lewis, Chair and Chief Executive Officer of Insmed.
  • Wise joined Insmed in 2014, holding positions of increasing responsibility in the Commercial organization and most recently serving as Senior Vice President, Head of U.S., and General Manager of ARIKAYCE.
  • Wise assuming more direct leadership of Insmed's commercial business, Roger Adsett, Chief Operating Officer, will focus on overseeing Insmed's overall business operations on a global basis, while continuing to provide valuable commercial insights and strategic perspective for the Company.

Nebulizers Global Market Research Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Monday, April 4, 2022
Medical Devices, Health, CAGR, Growth, Nurse Next Door Home Healthcare Services, Clinic, Noble gas, Tobacco, Hospital, Incidence, Asthma, Cystic fibrosis, Prevalence, Technology, COVID-19, PARI, Omron, COPD, Patient, Livestock, Pet

The global nebulizers market is expected to grow at a CAGR of 9.7% to nearly $1,453.3 million by 2025.

Key Points: 
  • The global nebulizers market is expected to grow at a CAGR of 9.7% to nearly $1,453.3 million by 2025.
  • The Pneumatic Nebulizer market was the largest segment of the nebulizers market by type, accounting for $429.3 million or 47.0% of the total market in 2020.
  • North America was the largest region in the nebulizers market, accounting for 50.0% of the global market in 2020.
  • The top growth potential in the nebulizers market by portability will arise in the Portable Nebulizer market, which will gain $702.2 million of global annual sales by 2025.